Literature DB >> 12960295

Cutting edge: Requirement for growth hormone-releasing hormone in the development of experimental autoimmune encephalomyelitis.

Hideto Ikushima1, Masaharu Kanaoka, Shinichi Kojima.   

Abstract

Growth hormone (GH)-releasing hormone (GHRH) is a neuropeptide that stimulates secretion of GH from the pituitary gland. Although GHRH and its receptor (GHRHR) are expressed in leukocytes, physiological function of GHRH in the immune system remains unclear. To study the influence of GHRH in autoimmunity, susceptibility to experimental autoimmune encephalomyelitis (EAE) was examined in C57BL/6J-Ghrhr(lit/lit) (lit/lit), mice deficient in the GHRHR gene. We found that lit/lit mice were resistant to myelin oligodendrocyte glycoprotein (MOG)-induced EAE. Splenocytes from MOG-immunized lit/lit mice proliferated normally in response to MOG peptide, suggesting that activation of MOG-specific T cells in GHRHR-deficient mice is not impaired. Our data strongly suggest that GHRH plays a crucial role in the development of EAE and may provide the basis for a novel therapeutic approach protecting from autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12960295     DOI: 10.4049/jimmunol.171.6.2769

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  2 in total

1.  Signaling mechanisms of growth hormone-releasing hormone receptor in LPS-induced acute ocular inflammation.

Authors:  Wei Cheng Liang; Jia Lin Ren; Qiu Xiao Yu; Jian Li; Tsz Kin Ng; Wai Kit Chu; Yong Jie Qin; Kai On Chu; Andrew V Schally; Chi Pui Pang; Sun On Chan
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-02       Impact factor: 11.205

2.  Antagonist of GH-releasing hormone receptors alleviates experimental ocular inflammation.

Authors:  Yong Jie Qin; Sun On Chan; Kelvin Kam Lung Chong; Benjamin Fuk Loi Li; Tsz Kin Ng; Yolanda Wong Ying Yip; Haoyu Chen; Mingzhi Zhang; Norman L Block; Herman S Cheung; Andrew V Schally; Chi Pui Pang
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-08       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.